A phase I trial on LBH589 (panobinostat), a histone deacetylase inhibitor in combination with external radiotherapy for the treatment of prostate cancer, oesophageal cancer and head and neck cancer: protocol CLBH589CBE01

deacetylase inhibitor - histones - phase I trial - radiotherapy

Radiotherapy is a keystone in the treatment of prostate cancer (PC), oesophageal cancer (EC) and head and neck cancer (HNC). In PC, LBH589 degrades androgen receptors, a key regulator for cancer cell survival and proliferation. In squamous cell cancer, LBH589 is synergistic with radiation in preclinical models. Generally, there is a strong rationale to use pan-histone deacetylase inhibitor (HDACi) in HNC and gastrointestinal cancer. A phase I trial designed to assess the feasibility of combined administration of different oral LBH589 dosages in combination with ionizing irradiation in a selection of patients with PC, HNC and EC is currently starting at CHU-Liège. This will allow the optimal dose-establishment for further studies.

For more information please contact:
Philippe A. Coucke, study coordinator
E-mail: pcoucke@chu.ulg.ac.be